Hormone Refractory Prostate Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
Condition: Hormone-refractory Prostate Cancer Intervention: Radiation: Palliative radiotherapy Sponsors: Zealand University Hospital; University of Schleswig-Holstein Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2018 Category: Research Source Type: clinical trials
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negati ve Breast Carcinoma Interventions: Drug: Capecitabine; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab Sponsors: Northwestern University; Merck Sharp & Dohme Corp.; National Cancer Institute (NCI) Not yet recruiting - verified February 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2017 Category: Research Source Type: clinical trials
